SARS coronary virus full virus vaccine

Abstract

One kind of vaccine composition is disclosed, and the vaccine composition contains the totivirus particle of early stage SARS virus and physiologically acceptable carrier. The use of the vaccine composition in preparing SARS resisting antibody and SARS virus infection preventing medicine is also disclosed.

Description

technical field [0001] The invention relates to the field of molecular epidemiology, in particular to a vaccine against severe acute respiratory syndrome virus and a preparation method thereof. Background technique [0002] In 2003, my country and many countries in the world were attacked by a large-scale atypical pneumonia (Atypical pneumonias). Severe acute respiratory syndrome (Severe Acute Respiratory Syndrome, SARS) caused by atypical pneumonia has occurred in 22 countries and regions. The World Health Organization (WHO) quickly established a collaborative research and monitoring network consisting of 13 laboratories in 10 countries around the world after the outbreak. On April 16, WHO officially confirmed that the pathogen of SARS was a new type of coronavirus, which is a single-stranded RNA virus. [0003] There have been more than 8,000 cases of atypical pneumonia in the world, and the death rate in some diseased areas has reached 15%, which has brought great panic ...

AI Technical Summary

Problems solved by technology

Because these viruses are middle and late SARS viruses, they are highly toxic and infectious, and they are very dangerous

And because the experimental animal monkey itself is not sensitive to the SARS virus, although the vaccine produces a small reaction in the monkey, it does not mean that the safety of the middle and late SARS whole virus vaccine has been effectively verified.

Images